Breaking News Instant updates and real-time market news.

DPLO

Diplomat Pharmacy

$20.31

0.3 (1.50%)

17:02
11/06/18
11/06
17:02
11/06/18
17:02

Diplomat Pharmacy raises FY18 EPS view to (10c)-3c from (15c)-1c

Raises upper end of FY18 revenue view to $5.5B-$5.7B from $5.5B-$5.9B. Consensus is for FY18 EPS 83c and for revenue $5.64B. Sees net income attributable to Diplomat between ($7.5M)-$2.6M; and adjusted EBITDA $164M-$170M.

  • 06

    Nov

DPLO Diplomat Pharmacy
$20.31

0.3 (1.50%)

07/23/18
WBLR
07/23/18
NO CHANGE
WBLR
Outperform
Diplomat Pharmacy recent selloff overdone, says William Blair
William Blair analyst John Kreger attributes the 20% pullback in shares of Diplomat Pharmacy from the June highs to growing concerns about the company's exposure to pharmaceutical rebates, which the Trump administration is seeking to regulate as part of a broader effort to lower drug prices for consumers. The analyst views the recent selloff as overdone. The vast majority of Diplomat's newly acquired pharmacy benefit management business is with commercial clients, rather than from Medicaid or Medicare Part D, Kreger tells investors in a research note. As such, any new regulations out of the Trump administration would presumably not affect PBM dealings with commercial clients, at least not directly, the analyst adds. Further, the analyst notes that rebates are just one of three broad ways in which PBMs are compensated by their clients. The other two are administrative per-claim fees and spread pricing on dispensed prescriptions. If rebates become less popular, the economics of the business could quickly shift to other payment mechanisms such as higher per-claim fees, Kreger contends. He does not view regulation of drug rebates as a long-term threat to the economics of the PBM business model for Diplomat or its larger peers. The analyst keeps an Outperform rating on Diplomat Pharmacy.
08/09/18
JPMS
08/09/18
NO CHANGE
Target $27
JPMS
Overweight
Diplomat Pharmacy selloff creates good entry point, says JPMorgan
After hosting investor meetings with management, JPMorgan analyst Lisa Gill says the recent pullback in shares of Diplomat Pharmacy provides a good entry point. The meetings were positive with management highlighting the growth opportunities in both the specialty and pharmacy benefit management businesses, Gill tells investors in a research note. Further, she viewed the company's commentary as favorable around the potential impact of President Trump's drug price blueprint. The analyst reiterates an Overweight rating on Diplomat Pharmacy with a $27 price target.
09/25/18
JPMS
09/25/18
NO CHANGE
JPMS
Overweight
Diplomat Pharmacy weakness on Gilead generics overdone, says JPMorgan
JPMorgan analyst Lisa Gill says the weakness yesterday in shares of Diplomat Pharmacy (DPLO) following Gilead's (GILD) announcement that it will be launching new authorized generic versions of hepatitis C treatments Epclusa and Harvoni is a "significant overreaction." Hepatitis C represents a relatively small portion of revenue for Diplomat Pharmacy, and as such, these two drugs are not material, Gill tells investors in a research note. Further, the analyst believes it is unclear whether payors will adopt the authorized generic in lieu of continuing to receive rebates on the branded drugs. In addition, Gill thinks Diplomat should be able to purchase the new authorized generics at a discount to the new list price with a higher gross margin spread relative to the brand. The analyst keeps an Overweight rating on the shares.
10/08/18
LSCM
10/08/18
NO CHANGE
Target $35
LSCM
Buy
Lake Street affirms Buy on Diplomat Pharmacy after talking to management
After speaking with CEO Brian Griffin and CFO Atul Kavthekar, Lake Street analyst Brooks O'Neil affirms a Buy rating on Diplomat Pharmacy with a $35 price target. The integration of last years' pharmacy benefit manager acquisitions continues to go very well and tailwinds "which have been blowing for DPLO have continued to blow," O'Neil tells investors in a research note. The analyst believes political and media rhetoric about changing rules for rebates in pharmacy services are unlikely to change the basic economics of the business. This type of "noise/activity has characterized the industry for several decades," the analyst contends. He expects "solid fundamentals" to continue to drive shares of Diplomat Pharmacy.

TODAY'S FREE FLY STORIES

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

07:44
02/19/19
02/19
07:44
02/19/19
07:44
Recommendations
XPO Logistics analyst commentary  »

XPO Logistics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:43
02/19/19
02/19
07:43
02/19/19
07:43
Hot Stocks
Noble Midstream sees FY19 capital budget $335M-$375M »

Noble Midstream's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:42
02/19/19
02/19
07:42
02/19/19
07:42
Hot Stocks
Noble Midstream sees adjusted EBITDA from partnership of at least $300M in 2020 »

Anticipates adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

CSX

CSX

$72.52

0.91 (1.27%)

07:41
02/19/19
02/19
07:41
02/19/19
07:41
Downgrade
CSX rating change  »

CSX downgraded to Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    May

HEXO

HEXO Corp

$5.57

0.17 (3.15%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Initiation
HEXO Corp initiated  »

HEXO Corp initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Downgrade
Windstream rating change  »

Windstream downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

AMSC

AMSC

$15.00

-0.8 (-5.06%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Conference/Events
AMSC management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:40
02/19/19
02/19
07:40
02/19/19
07:40
Hot Stocks
Noble Midstream sees FY19 adjusted EBITDA $340M-$390M »

"Entering 2019, we…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

07:40
02/19/19
02/19
07:40
02/19/19
07:40
General news
Treasury Market Outlook: bond yields have dipped slightly lower amid risk-off flows »

Treasury Market Outlook:…

CEQP

Crestwood Equity

$32.82

-0.06 (-0.18%)

07:39
02/19/19
02/19
07:39
02/19/19
07:39
Earnings
Crestwood Equity sees FY19 net income $105M-$135M »

Sees FY 19 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

PODD

Insulet

$88.51

3.68 (4.34%)

07:38
02/19/19
02/19
07:38
02/19/19
07:38
Recommendations
Insulet analyst commentary  »

Insulet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

NWL

Newell Brands

$17.15

-4.55 (-20.97%)

07:38
02/19/19
02/19
07:38
02/19/19
07:38
Recommendations
Newell Brands analyst commentary  »

Newell Brands price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

CEQP

Crestwood Equity

$32.82

-0.06 (-0.18%)

07:38
02/19/19
02/19
07:38
02/19/19
07:38
Earnings
Crestwood Equity reports Q4 EPS 57c, may not compare to consensus 13c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

IRBT

iRobot

$119.34

4 (3.47%)

07:38
02/19/19
02/19
07:38
02/19/19
07:38
Downgrade
iRobot rating change  »

iRobot downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPC

W.P. Carey

$75.16

-0.02 (-0.03%)

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Hot Stocks
W.P. Carey to invest $75M in food production facility in San Antonio »

W. P. Carey announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

EBAY

eBay

$36.59

0.28 (0.77%)

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Recommendations
eBay analyst commentary  »

eBay January trends…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

MIDD

Middleby

$126.19

2.13 (1.72%)

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Hot Stocks
Middleby announces retirement of CEO Selim Bassoul »

The Middleby Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Recommendations
PepsiCo analyst commentary  »

PepsiCo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 18

    May

PATK

Patrick Industries

$47.06

2.01 (4.46%)

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Recommendations
Patrick Industries analyst commentary  »

Patrick Industries price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SB

Safe Bulkers

$1.60

-0.01 (-0.62%)

07:35
02/19/19
02/19
07:35
02/19/19
07:35
Earnings
Safe Bulkers reports Q4 adj. EPS 7c, consensus 8c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NXRT

NexPoint Residential

$38.40

0.13 (0.34%)

07:35
02/19/19
02/19
07:35
02/19/19
07:35
Earnings
NexPoint Residential sees FY19 AFFO $2.16, consensus $2.24 »

Sees FY19 Same Store NOI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

DE

Deere

$158.99

-3.45 (-2.12%)

07:35
02/19/19
02/19
07:35
02/19/19
07:35
Recommendations
Deere analyst commentary  »

Too early to write off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 27

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

07:34
02/19/19
02/19
07:34
02/19/19
07:34
Hot Stocks
Biohaven Pharmaceutical's verdiperstat receives FDA orphan drug designation »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$47.54

1.49 (3.24%)

07:34
02/19/19
02/19
07:34
02/19/19
07:34
Downgrade
Canopy Growth rating change  »

Canopy Growth downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NXRT

NexPoint Residential

$38.40

0.13 (0.34%)

07:33
02/19/19
02/19
07:33
02/19/19
07:33
Earnings
NexPoint Residential reports Q4 AFFO 47c, consensus 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.